Pro: Can Biomarkers be Gold Standards in Alzheimer's Disease?

DSpace/Manakin Repository

Pro: Can Biomarkers be Gold Standards in Alzheimer's Disease?

Citable link to this page

 

 
Title: Pro: Can Biomarkers be Gold Standards in Alzheimer's Disease?
Author: Sperling, Reisa Anne; Johnson, Keith Alan

Note: Order does not necessarily reflect citation order of authors.

Citation: Sperling, Reisa, and Keith Johnson. 2010. Pro: Can biomarkers be gold standards in Alzheimer's disease?. Alzheimer's Research & Therapy 2: 17.
Full Text & Related Files:
Abstract: Recent advances in biomarkers for Alzheimer’s disease (AD) now allow the visualization of one of the hallmark pathologies of AD in vivo, and combination biomarker profiles can now approximate the diagnostic accuracy of autopsy in patients with dementia. Biomarkers are already employed in clinical trials in prodromal AD for both subject selection and in monitoring therapeutic response. Ultimately the greatest utility of biomarkers may be in the preclinical stages of AD, to identify and track progression of the disease prior to significant cognitive impairment, at the point when disease modifying therapies are likely to be most efficacious.
Published Version: doi://10.1186/alzrt41
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919697/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8296038
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters